Left ventricular restoration devices post myocardial infarction

Tom Hendriks, Remco A J Schurer, Lawien Al Ali, Ad F M van den Heuvel, Pim van der Harst, Tom Hendriks, Remco A J Schurer, Lawien Al Ali, Ad F M van den Heuvel, Pim van der Harst

Abstract

Even in the era of percutaneous reperfusion therapy, left ventricular (LV) remodeling after myocardial infarction (MI) leading to heart failure remains a major health concern. Contractile dysfunction of the infarcted myocardium results in an increased pressure load, leading to maladaptive reshaping of the LV. Several percutaneous transcatheter procedures have been developed to deliver devices that restore LV shape and function. The purposes of this review are to discuss the spectrum of transcatheter devices that are available or in development for attenuation of adverse LV remodeling and to critically examine the available evidence for improvement of functional status and cardiovascular outcomes.

Keywords: Left ventricular remodeling; Left ventricular restoration; Myocardial infarction; Transcatheter devices.

Conflict of interest statement

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Figures

Fig. 1
Fig. 1
An overview of the discussed transcatheter left ventricular restoration devices, grouped by indication for use based on the stage of adverse left ventricular remodeling post myocardial infarction. The represented transvenous annuloplasty device is the mitral loop cerclage, the other devices are differently shaped

References

    1. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35:569–582. doi: 10.1016/S0735-1097(99)00630-0.
    1. Bhatt AS, Ambrosy AP, Velazquez EJ. Adverse remodeling and reverse remodeling after myocardial infarction. Curr Cardiol Rep. 2017;19:71. doi: 10.1007/s11886-017-0876-4.
    1. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44–51. doi: 10.1161/01.CIR.76.1.44.
    1. Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray J, Pfeffer MA. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation. 2005;111:3411–3419. doi: 10.1161/CIRCULATIONAHA.104.508093.
    1. Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM, Antoniucci D. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation. 2002;106:2351–2357. doi: 10.1161/01.CIR.0000036014.90197.FA.
    1. Moller JE, Hillis GS, Oh JK, Reeder GS, Gersh BJ, Pellikka PA. Wall motion score index and ejection fraction for risk stratification after acute myocardial infarction. Am Heart J. 2006;151:419–425. doi: 10.1016/j.ahj.2005.03.042.
    1. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol. 2010;56:392–406. doi: 10.1016/j.jacc.2010.05.011.
    1. Racchi M, Govoni S, Lucchelli A, Capone L, Giovagnoni E. Insights into the definition of terms in European medical device regulation. Expert Rev Med Devices. 2016;13:907–917. doi: 10.1080/17434440.2016.1224644.
    1. Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 1995;27:1281–1292. doi: 10.1016/S0022-2828(05)82390-9.
    1. Gajarsa JJ, Kloner RA. Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev. 2011;16:13–21. doi: 10.1007/s10741-010-9181-7.
    1. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging. 2011;4:98–108. doi: 10.1016/j.jcmg.2010.10.008.
    1. van den Heuvel AF, van Veldhuisen DJ, van der Wall EE, et al. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2000;35:19–28. doi: 10.1016/S0735-1097(99)00499-4.
    1. Yousef ZR, Redwood SR, Marber MS. Postinfarction left ventricular remodelling: where are the theories and trials leading us? Heart. 2000;83:76–80. doi: 10.1136/heart.83.1.76.
    1. Springeling T, Kirschbaum SW, Rossi A, Baks T, Karamermer Y, Schulz C, Ouhlous M, Duncker DJ, Moelker A, Krestin GP, Serruys PWJC, de Feyter P, van Geuns RJM. Late cardiac remodeling after primary percutaneous coronary intervention-five-year cardiac magnetic resonance imaging follow-up. Circ J. 2013;77:81–88. doi: 10.1253/circj.CJ-12-0043.
    1. Orn S, Manhenke C, Anand IS, et al. Effect of left ventricular scar size, location, and transmurality on left ventricular remodeling with healed myocardial infarction. Am J Cardiol. 2007;99:1109–1114. doi: 10.1016/j.amjcard.2006.11.059.
    1. Levine RA, Schwammenthal E. Ischemic mitral regurgitation on the threshold of a solution: from paradoxes to unifying concepts. Circulation. 2005;112:745–758. doi: 10.1161/CIRCULATIONAHA.104.486720.
    1. Writing Group Members. Mozaffarian D, Benjamin EJ, et al. Executive summary: heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133:447–454. doi: 10.1161/CIR.0000000000000366.
    1. Taniguchi T, Shiomi H, Morimoto T, Watanabe H, Ono K, Shizuta S, Kato T, Saito N, Kaji S, Ando K, Kadota K, Furukawa Y, Nakagawa Y, Horie M, Kimura T. Incidence and prognostic impact of heart failure hospitalization during follow-up after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. Am J Cardiol. 2017;119:1729–1739. doi: 10.1016/j.amjcard.2017.03.013.
    1. O’Gara PT, Kushner FG, Ascheim DD, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:529–555. doi: 10.1161/CIR.0b013e3182742c84.
    1. Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2017
    1. Kinno M, Nagpal P, Horgan S, Waller AH. Comparison of echocardiography, cardiac magnetic resonance, and computed tomographic imaging for the evaluation of left ventricular myocardial function: part 1 (global assessment) Curr Cardiol Rep. 2017;1:19. doi: 10.1007/s11886-017-0815-4.
    1. Writing Committee Members. Yancy CW, Jessup M, et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240–e327.
    1. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–e161. doi: 10.1161/CIR.0000000000000509.
    1. Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975. doi: 10.1002/ejhf.592.
    1. Cooley DA, Collins HA, Morris GC, Jr, Chapman DW. Ventricular aneurysm after myocardial infarction; surgical excision with use of temporary cardiopulmonary bypass. J Am Med Assoc. 1958;167:557–560. doi: 10.1001/jama.1958.02990220027008.
    1. Cooley DA, Frazier OH, Duncan JM, Reul GJ, Krajcer Z. Intracavitary repair of ventricular aneurysm and regional dyskinesia. Ann Surg. 1992;215:417–423. doi: 10.1097/00000658-199205000-00003.
    1. Di Donato M, Sabatier M, Dor V, Toso A, Maioli M, Fantini F. Akinetic versus dyskinetic postinfarction scar: relation to surgical outcome in patients undergoing endoventricular circular patch plasty repair. J Am Coll Cardiol. 1997;29:1569–1575. doi: 10.1016/S0735-1097(97)00092-2.
    1. Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O’Connor CM, Hill JA, Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL, Lee KL, STICH Hypothesis 2 Investigators Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med. 2009;360:1705–1717. doi: 10.1056/NEJMoa0900559.
    1. Carpentier A, Chachques JC. Myocardial substitution with a stimulated skeletal muscle: first successful clinical case. Lancet. 1985;1:1267. doi: 10.1016/S0140-6736(85)92329-3.
    1. Furnary AP, Jessup FM, Moreira LP. Multicenter trial of dynamic cardiomyoplasty for chronic heart failure. The American Cardiomyoplasty Group. J Am Coll Cardiol. 1996;28:1175–1180. doi: 10.1016/S0735-1097(96)00298-7.
    1. Mann DL, Acker MA, Jessup M, Sabbah HN, Starling RC, Kubo SH, Acorn Trial Principal Investigators and Study Coordinators Clinical evaluation of the CorCap cardiac support device in patients with dilated cardiomyopathy. Ann Thorac Surg. 2007;84:1226–1235. doi: 10.1016/j.athoracsur.2007.03.095.
    1. Starling RC, Jessup M, Oh JK, Sabbah HN, Acker MA, Mann DL, Kubo SH. Sustained benefits of the CorCap cardiac support device on left ventricular remodeling: three year follow-up results from the Acorn clinical trial. Ann Thorac Surg. 2007;84:1236–1242. doi: 10.1016/j.athoracsur.2007.03.096.
    1. Acker MA, Jessup M, Bolling SF, Oh J, Starling RC, Mann DL, Sabbah HN, Shemin R, Kirklin J, Kubo SH. Mitral valve repair in heart failure: five-year follow-up from the mitral valve replacement stratum of the Acorn randomized trial. J Thorac Cardiovasc Surg. 2011;142:569–74, 574.e1. doi: 10.1016/j.jtcvs.2010.10.051.
    1. Mann DL, Kubo SH, Sabbah HN, Starling RC, Jessup M, Oh JK, Acker MA. Beneficial effects of the CorCap cardiac support device: five-year results from the Acorn trial. J Thorac Cardiovasc Surg. 2012;143:1036–1042. doi: 10.1016/j.jtcvs.2011.06.014.
    1. Wechsler AS, Sadowski J, Kapelak B, Bartus K, Kalinauskas G, Rucinskas K, Samalavicius R, Annest L. Durability of epicardial ventricular restoration without ventriculotomy. Eur J Cardiothorac Surg. 2013;44:e189–e192. doi: 10.1093/ejcts/ezt292.
    1. Cheng Y, Aboodi MS, Wechsler AS, Kaluza GL, Granada JF, van Bladel K, Annest LS, Yi GH. Epicardial catheter-based ventricular reconstruction: a novel therapy for ischaemic heart failure with anteroapical aneurysm. Interact Cardiovasc Thorac Surg. 2013;17:915–922. doi: 10.1093/icvts/ivt387.
    1. Hernández-Enríquez M, Brugaletta S, Castellá M, et al. New transcatheter treatment of the dilated ischaemic cardiomyopathy with Revivent system. Abstract presented at EuroPCR 2016
    1. Mazzaferri EL, Jr GS, Sagic D, et al. Percutaneous left ventricular partitioning in patients with chronic heart failure and a prior anterior myocardial infarction: results of the PercutAneous Ventricular RestorAtion in Chronic Heart failUre PaTiEnts trial. Am Heart J. 2012;163:812–820.e1. doi: 10.1016/j.ahj.2012.02.013.
    1. Costa MA, Mazzaferri EL, Jr SH, Abraham WT. Percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure: three-year outcomes of the PARACHUTE first-in-human study. Circ Heart Fail. 2014;7:752–758. doi: 10.1161/CIRCHEARTFAILURE.114.001127.
    1. Thomas M, Nienaber CA, Ince H, Erglis A, Vukcevic V, Schäfer U, Ferreira RC, Hardt S, Verheye S, Gama Ribeiro V, Sugeng L, Tamburino C. Percutaneous ventricular restoration (PVR) therapy using the Parachute device in 100 subjects with ischaemic dilated heart failure: one-year primary endpoint results of PARACHUTE III, a European trial. EuroIntervention. 2015;11:710–717. doi: 10.4244/EIJV11I6A143.
    1. Costa MA, Pencina M, Nikolic S, Engels T, Templin B, Abraham WT. The PARACHUTE IV trial design and rationale: percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure and dilated left ventricles. Am Heart J. 2013;165:531–536. doi: 10.1016/j.ahj.2012.12.022.
    1. Schmidt T, Frerker C, Thielsen T, Dotz I, Wohlmuth P, Kuck KH, Schäfer U. New evidence for favourable effects on haemodynamics and ventricular performance after Parachute((R)) implantation in humans. Eur J Heart Fail. 2014;16:1112–1119. doi: 10.1002/ejhf.160.
    1. Yun CH, Sun JY, Templin B, Lin SH, Chen KM, Wu TH, Hung CL, Liu CC, Hsu HH, Alaiti MA, Fares A, DeCicco A, Bezerra HG. Improvements in left ventricular diastolic mechanics after parachute device implantation in patients with ischemia heart failure: a cardiac computerized tomographic study. J Card Fail. 2017;23:455–463. doi: 10.1016/j.cardfail.2017.04.011.
    1. Tam CC, Fares A, Alaiti A, Shaikh K, Ince H, Erglis A, Bezerra HG, Abraham WT, Costa MA, Attizzani GF. Cardiac computed tomography assessment of the near term impact of percutaneous ventricular restoration therapy (Parachute((R))) on mitral valve geometry. Catheter Cardiovasc Interv. 2016;88:E45–E51. doi: 10.1002/ccd.26291.
    1. Ladich E, Otsuka F, Virmani R. A pathologic study of explanted parachute devices from seven heart failure patients following percutaneous ventricular restoration. Catheter Cardiovasc Interv. 2014;83:619–630. doi: 10.1002/ccd.25010.
    1. Grossi EA, Patel N, Woo YJ, Goldberg JD, Schwartz CF, Subramanian V, Feldman T, Bourge R, Baumgartner N, Genco C, Goldman S, Zenati M, Wolfe JA, Mishra YK, Trehan N, Mittal S, Shang S, Mortier TJ, Schweich CJ Jr, RESTOR-MV Study Group Outcomes of the RESTOR-MV trial (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve) J Am Coll Cardiol. 2010;56:1984–1993. doi: 10.1016/j.jacc.2010.06.051.
    1. Pedersen WR, Block P, Leon M, Kramer P, Kapadia S, Babaliaros V, Kodali S, Tuzcu EM, Feldman T. iCoapsys mitral valve repair system: percutaneous implantation in an animal model. Catheter Cardiovasc Interv. 2008;72:125–131. doi: 10.1002/ccd.21551.
    1. Rogers JH, Rahdert DA, Caputo GR, Takeda PA, Palacios IF, Tio FO, Taylor EA, Low RI. Long-term safety and durability of percutaneous septal sinus shortening (the PS(3) system) in an ovine model. Catheter Cardiovasc Interv. 2009;73:540–548. doi: 10.1002/ccd.21818.
    1. Palacios IF, Condado JA, Brandi S, Rodriguez V, Bosch F, Silva G, Low RI, Rogers JH. Safety and feasibility of acute percutaneous septal sinus shortening: first-in-human experience. Catheter Cardiovasc Interv. 2007;69:513–518. doi: 10.1002/ccd.21070.
    1. Pighi M, Estevez-Loureiro R, Maisano F, Ussia GP, Dall’Ara G, Franzen O, Laroche C, Settergren M, Winter R, Nickenig G, Gilard M, di Mario C, Transcatheter Valve Treatment Sentinel Registry (TCVT) Investigators of the EURObservational Research Programme (EORP) of the European Society of Cardiology Immediate and 12-month outcomes of ischemic versus nonischemic functional mitral regurgitation in patients treated with MitraClip (from the 2011 to 2012 pilot sentinel registry of percutaneous edge-to-edge mitral valve repair of the European Society of Cardiology) Am J Cardiol. 2017;119:630–637. doi: 10.1016/j.amjcard.2016.10.049.
    1. Feldman T, Kar S, Elmariah S, Smart SC, Trento A, Siegel RJ, Apruzzese P, Fail P, Rinaldi MJ, Smalling RW, Hermiller JB, Heimansohn D, Gray WA, Grayburn PA, Mack MJ, Lim DS, Ailawadi G, Herrmann HC, Acker MA, Silvestry FE, Foster E, Wang A, Glower DD, Mauri L, EVEREST II Investigators Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol. 2015;66:2844–2854. doi: 10.1016/j.jacc.2015.10.018.
    1. Harnek J, Webb JG, Kuck KH, Tschope C, Vahanian A, Buller CE, James SK, Tiefenbacher CP, Stone GW. Transcatheter implantation of the MONARC coronary sinus device for mitral regurgitation: 1-year results from the EVOLUTION phase I study (clinical evaluation of the Edwards Lifesciences percutaneous mitral annuloplasty system for the treatment of mitral regurgitation) JACC Cardiovasc Interv. 2011;4:115–122. doi: 10.1016/j.jcin.2010.08.027.
    1. Machaalany J, Bilodeau L, Hoffmann R, Sack S, Sievert H, Kautzner J, Hehrlein C, Serruys P, Sénéchal M, Douglas P, Bertrand OF. Treatment of functional mitral valve regurgitation with the permanent percutaneous transvenous mitral annuloplasty system: results of the multicenter international percutaneous transvenous mitral Annuloplasty system to reduce mitral valve regurgitation in patients with heart failure trial. Am Heart J. 2013;165:761–769. doi: 10.1016/j.ahj.2013.01.010.
    1. Radermecker MA, Lancellotti P, Legrand V, Pierard L. Delayed asymptomatic thrombosis and erosion of the coronary sinus after transvenous mitral annuloplasty with the Viacor device. Ann Thorac Surg. 2016;101:2391. doi: 10.1016/j.athoracsur.2016.01.073.
    1. Machaalany J, St-Pierre A, Senechal M, et al. Fatal late migration of viacor percutaneous transvenous mitral annuloplasty device resulting in distal coronary venous perforation. Can J Cardiol. 2013;29:130.e1–130.e4. doi: 10.1016/j.cjca.2012.03.014.
    1. Schofer J, Siminiak T, Haude M, Herrman JP, Vainer J, Wu JC, Levy WC, Mauri L, Feldman T, Kwong RY, Kaye DM, Duffy SJ, Tubler T, Degen H, Brandt MC, van Bibber R, Goldberg S, Reuter DG, Hoppe UC. Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union study. Circulation. 2009;120:326–333. doi: 10.1161/CIRCULATIONAHA.109.849885.
    1. Siminiak T, Wu JC, Haude M, Hoppe UC, Sadowski J, Lipiecki J, Fajadet J, Shah AM, Feldman T, Kaye DM, Goldberg SL, Levy WC, Solomon SD, Reuter DG. Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN trial. Eur J Heart Fail. 2012;14:931–938. doi: 10.1093/eurjhf/hfs076.
    1. Lipiecki Janusz, Siminiak Tomasz, Sievert Horst, Müller-Ehmsen Jochen, Degen Hubertus, Wu Justina C, Schandrin Christian, Kalmucki Piotr, Hofmann Ilona, Reuter David, Goldberg Steven L, Haude Michael. Coronary sinus-based percutaneous annuloplasty as treatment for functional mitral regurgitation: the TITAN II trial. Open Heart. 2016;3(2):e000411. doi: 10.1136/openhrt-2016-000411.
    1. Goldberg SL, Meredith I, Marwick T, Haluska BA, Lipiecki J, Siminiak T, Mehta N, Kaye DM, Sievert H, REDUCE FMR Investigators A randomized double-blind trial of an interventional device treatment of functional mitral regurgitation in patients with symptomatic congestive heart failure-trial design of the REDUCE FMR study. Am Heart J. 2017;188:167–174. doi: 10.1016/j.ahj.2017.02.032.
    1. Park YH, Chon MK, Lederman RJ, Sung SC, Je HG, Choo KS, Lee SH, Shin ES, Kim JS, Hwang KW, Lee SY, Chun KJ, Kim CM, Kim JH. Mitral loop cerclage annuloplasty for secondary mitral regurgitation: first human results. JACC Cardiovasc Interv. 2017;10:597–610. doi: 10.1016/j.jcin.2016.12.282.
    1. Frey N, Linke A, Suselbeck T, Muller-Ehmsen J, Vermeersch P, Schoors D, Rosenberg M, Bea F, Tuvia S, Leor J. Intracoronary delivery of injectable bioabsorbable scaffold (IK-5001) to treat left ventricular remodeling after ST-elevation myocardial infarction: a first-in-man study. Circ Cardiovasc Interv. 2014;7:806–812. doi: 10.1161/CIRCINTERVENTIONS.114.001478.
    1. Rao SV, Zeymer U, Douglas PS, al-Khalidi H, Liu J, Gibson CM, Harrison RW, Joseph DS, Heyrman R, Krucoff MW. A randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of intracoronary application of a novel bioabsorbable cardiac matrix for the prevention of ventricular remodeling after large ST-segment elevation myocardial infarction: rationale and design of the PRESERVATION I trial. Am Heart J. 2015;170:929–937. doi: 10.1016/j.ahj.2015.08.017.
    1. Ryan LP, Matsuzaki K, Noma M, Jackson BM, Eperjesi TJ, Plappert TJ, St. John-Sutton MG, Gorman JH, III, Gorman RC. Dermal filler injection: a novel approach for limiting infarct expansion. Ann Thorac Surg. 2009;87:148–155. doi: 10.1016/j.athoracsur.2008.09.028.
    1. Dixon JA, Gorman RC, Stroud RE, Mukherjee R, Meyer EC, Baker NL, Morita M, Hamamoto H, Ryan LP, Gorman JH, Spinale FG. Targeted regional injection of biocomposite microspheres alters post-myocardial infarction remodeling and matrix proteolytic pathways. Circulation. 2011;124:S35–S45. doi: 10.1161/CIRCULATIONAHA.111.035774.
    1. McGarvey JR, Kondo N, Witschey WR, et al. Injectable microsphere gel progressively improves global ventricular function, regional contractile strain, and mitral regurgitation after myocardial infarction. Ann Thorac Surg. 2015;99:597–603. doi: 10.1016/j.athoracsur.2014.09.014.
    1. Rodell CB, Lee ME, Wang H, Takebayashi S, Takayama T, Kawamura T, Arkles JS, Dusaj NN, Dorsey SM, Witschey WRT, Pilla JJ, Gorman JH, III, Wenk JF, Burdick JA, Gorman RC. Injectable shear-thinning hydrogels for minimally invasive delivery to infarcted myocardium to limit left ventricular remodeling. Circ Cardiovasc Interv. 2016;9:e004058. doi: 10.1161/CIRCINTERVENTIONS.116.004058.
    1. Dorsey SM, McGarvey JR, Wang H, et al. MRI evaluation of injectable hyaluronic acid-based hydrogel therapy to limit ventricular remodeling after myocardial infarction. Biomaterials. 2015;69:65–75. doi: 10.1016/j.biomaterials.2015.08.011.
    1. Gooley RP, Meredith IT. The Accucinch transcatheter direct mitral valve annuloplasty system. EuroIntervention. 2015;11(Suppl W):W60–W61. doi: 10.4244/EIJV11SWA16.
    1. Fieno DS, Kim RJ, Chen EL, Lomasney JW, Klocke FJ, Judd RM. Contrast-enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing. J Am Coll Cardiol. 2000;36:1985–1991. doi: 10.1016/S0735-1097(00)00958-X.
    1. Singelyn JM, Sundaramurthy P, Johnson TD, Schup-Magoffin PJ, Hu DP, Faulk DM, Wang J, Mayle KM, Bartels K, Salvatore M, Kinsey AM, DeMaria AN, Dib N, Christman KL. Catheter-deliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction. J Am Coll Cardiol. 2012;59:751–763. doi: 10.1016/j.jacc.2011.10.888.
    1. Seif-Naraghi SB, Singelyn JM, Salvatore MA, Osborn KG, Wang JJ, Sampat U, Kwan OL, Strachan GM, Wong J, Schup-Magoffin PJ, Braden RL, Bartels K, DeQuach JA, Preul M, Kinsey AM, DeMaria AN, Dib N, Christman KL. Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction. Sci Transl Med. 2013;5:173ra25. doi: 10.1126/scitranslmed.3005503.
    1. Wassenaar JW, Gaetani R, Garcia JJ, Braden RL, Luo CG, Huang D, DeMaria AN, Omens JH, Christman KL. Evidence for mechanisms underlying the functional benefits of a myocardial matrix hydrogel for post-MI treatment. J Am Coll Cardiol. 2016;67:1074–1086. doi: 10.1016/j.jacc.2015.12.035.
    1. Mann DL, Lee RJ, Coats AJ, et al. One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure. Eur J Heart Fail. 2016;18:314–325. doi: 10.1002/ejhf.449.
    1. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JGF, Cohn JN, Dickstein K, Domanski MJ, Ekman I, Filippatos GS, Gheorghiade M, Hernandez AF, Jaarsma T, Koglin J, Konstam M, Kupfer S, Maggioni AP, Mebazaa A, Metra M, Nowack C, Pieske B, Piña IL, Pocock SJ, Ponikowski P, Rosano G, Ruilope LM, Ruschitzka F, Severin T, Solomon S, Stein K, Stockbridge NL, Stough WG, Swedberg K, Tavazzi L, Voors AA, Wasserman SM, Woehrle H, Zalewski A, McMurray JJV. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail. 2013;15:1082–1094. doi: 10.1093/eurjhf/hft095.
    1. Jonas Wayne B, Crawford Cindy, Colloca Luana, Kaptchuk Ted J, Moseley Bruce, Miller Franklin G, Kriston Levente, Linde Klaus, Meissner Karin. To what extent are surgery and invasive procedures effective beyond a placebo response? A systematic review with meta-analysis of randomised, sham controlled trials. BMJ Open. 2015;5(12):e009655. doi: 10.1136/bmjopen-2015-009655.
    1. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL, SYMPLICITY HTN-3 Investigators A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–1401. doi: 10.1056/NEJMoa1402670.
    1. Official Journal of the European Union. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC. 2017:L 117
    1. Uriel N, Colombo PC, Cleveland JC, Long JW, Salerno C, Goldstein DJ, Patel CB, Ewald GA, Tatooles AJ, Silvestry SC, John R, Caldeira C, Jeevanandam V, Boyle AJ, Sundareswaran KS, Sood P, Mehra MR. Hemocompatibility-related outcomes in the MOMENTUM 3 trial at 6 months: a randomized controlled study of a fully magnetically levitated pump in advanced heart failure. Circulation. 2017;135:2003–2012. doi: 10.1161/CIRCULATIONAHA.117.028303.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe